| Literature DB >> 29311586 |
Aline Götze1, Sophie von Keyserlingk2, Sabine Peschel1, Ulrike Jacoby2, Corinna Schreiver2, Bernd Köhler3, Stephan Allgeier3, Karsten Winter4, Martin Röhlig5, Anselm Jünemann1, Rainer Guthoff6, Oliver Stachs1, Dagmar-C Fischer7.
Abstract
Optical coherence tomography (OCT) of the retina and corneal confocal laser scanning microscopy (CLSM) of the subbasal nerve plexus (SBP) are noninvasive techniques for quantification of the ocular neurodegenerative changes in individuals with type 1 diabetes mellitus (T1DM). In adult T1DM patients these changes are hardly related to T1DM only. Instead, ageing and/or lifestyle associated comorbidities have to be considered as putative confounding variables. Therefore, we investigated pediatric T1DM patients (n = 28; 14.2 ± 2.51 y; duration of disease: 5.39 ± 4.16 y) without clinical signs of diabetic retina disease, neuropathy, vasculopathy or nephropathy and compared our findings with those obtained in healthy controls (n = 46; 14.8 ± 1.89 y). The SBP was characterized by the averaged length, thickness, and tortuosity of nerve fibers as well as the number of branching and connecting points. OCT was used to determine the total thickness of the retina (ALL) and the thickness of each retinal layer. Both methods revealed signs of early neurodegenerative changes, e.g. thinning of distinct retinal layers at the pericentral ring and shortening of corneal nerve fibers that are already present in pediatric T1DM patients. Standardization of instruments and algorithms are urgently required to enable uniform comparison between different groups and define normative values to introduce in the clinical setting.Entities:
Mesh:
Year: 2018 PMID: 29311586 PMCID: PMC5758564 DOI: 10.1038/s41598-017-18284-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Anthropometric and clinical characteristics of patients and controls.
| CLSM | OCT and CLSM | |||
|---|---|---|---|---|
| Patients (10 f/18 m) | Controls (28 f/18 m) | Patients (10 f/16 m) | Controls (16 f/14 m) | |
| Age [year] | 14.2 ± 2.54 | 14.8 ± 1.89 | 14.5 ± 2.23 | 14.5 ± 1.98 |
| Height [SDS] | 0.06 ± 0.88 | 0.58 ± 1.20 | 0.15 ± 0.89 | 0.66 ± 1.20 |
| Weight [SDS] | 0.23 ± 0.93 | 0.46 ± 1.00 | 0.31 ± 0.97 | 0.59 ± 0.94 |
| BMI [SDS] | 0.25 ± 0.92 | 0.26 ± 0.84 | 0.30 ± 0.96 | 0.37 ± 0.80 |
| BPsys [SDS] | 1.94 ± 1.17* | 1.27 ± 1.16* | 1.95 ± 1.20 | 1.39 ± 1.18 |
| BPdias [SDS] | 0.89 ± 0.74* | 0.36 ± 0.88* | 0.90 ± 0.76 | 0.50 ± 0.97 |
| Duration of disease [year] | 4.23 (1.2–15.5) | 4.44 (1.2–15.5) | ||
| Mean daily insulin dosage [IU/kg] | 0.38 ± 0.15 | 0.39 ± 0.14 | ||
| Actual HbA1c [%] | 8.73 ± 2.00 | 8.96 ± 1.86 | ||
| Mean HbA1c [%] | 8.64 ± 1.53 | 8.73 ± 1.51 | ||
Results are given as mean ± standard deviation and as median (min, max) for all participants undergoing CLSM and for the subgroups undergoing OCT and CLSM. *Significant difference between patients and controls.
Figure 1Representative images from a T1DM patient (left) and control (right). Automatically generated thickness maps and segmented boundaries of ganglion cell layer and the inner plexiform layer were presented.
Figure 2Significant differences (each p < 0.05) of the pericentral thickness of the RNFL (A), the GCL (B) and ALL (C) in patients (black circles) and controls (blue circles).
Thickness of the foveal retinal layers and of the pericentral OPL in patients on MDI and CSII therapy.
| CSII (5 f/6 m) | MDI (6 f/9 m) | p | |
|---|---|---|---|
| Foveal thickness of the | |||
| GCL [µm] | 15.33 (10.00–21.67) | 18.67 (14.00–42.67) | 0.038 |
| IPL [µm] | 20.00 (17.67–26.33) | 25.00 (20.33–38.33) | 0.035 |
| INL [µm] | 17.67 (12.67–24.67) | 20.33 (17.00–32.67) | 0.021 |
| OPL [µm] | 25.67* (16.33–32.33) | 29.33 (21.33–36.33) | 0.038 |
| ALL [µm] | 270.7* (232.0–302.0) | 290.0 (256.7–327.3) | 0.024 |
| pericentral thickness of the | |||
| OPL [µm] | 34.58 (30.08–40.50) | 32.58 (28.42–35.08) | 0.029 |
Data are given as median and range. ALL, total thickness of retina; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer. *p < 0.05 compared to controls.
Figure 3The typical mosaic image of the SBP of a patient (A), healthy control (B) and schematic representation of skeletonized images used for characterization of the SBP in patients (C) and healthy controls (D).
Figure 4Significant differences between CNFL (A) p < 0.05), CNFTo (B) p < 0.01), CNSFL (C) p < 0.005) and CNFTh (D) p < 0.005) in patients (black circles) and controls (blue circles).
Results of the CLSM in pediatric T1DM patients and healthy controls.
| Patients (10 f/18 m) | Controls (28 f/18 m) | p | |
|---|---|---|---|
| Results for | |||
| CNFD [mm−2] | 249 (84.0–503) | 252 (126–641) | 0.832 |
| CNBD [mm−2] | 135 (27.9–302) | 123 (52.4–397) | 0.798 |
| CNCP [mm−2] | 73.9 (10.6–159) | 77.3 (22.6–153) | 0.196 |
CNFD, corneal nerve fiber density; CNBD, corneal nerve fiber branch density; CNCP, corneal nerve connecting points.
Figure 5Correlations between CNFD and the peripheral RNFL thickness (A) and between CNCP and the pericentral INL thickness (B) in T1DM patients. A, R = 0.52, p < 0.01; B, R = 0.54, p < 0.01.
Figure 6Foveal INL thickness (A), pericentral RNFL thickness (B) and CNFTo (C) relative to the basal insulin dosage in T1DM patients. A, R = −0.48, p < 0.05; B, R = −0.43, p < 0.05; C, R = 0.55, p < 0.005.